Diabetes Mellitus Epidemiology

Diabetes mellitus epidemiology studies the frequency, distribution, and determinants of diabetes - a group of metabolic disorders characterised by chronic hyperglycaemia - across populations. Driven largely by rising type 2 diabetes, the global prevalence has climbed steeply, making diabetes one of the defining chronic-disease epidemics of the era.

Definition

The branch of epidemiology concerned with the occurrence, distribution, determinants, and consequences of diabetes mellitus in populations, with particular attention to type 2 diabetes and its complications.

Scope

The entry covers how diabetes is classified and diagnosed for surveillance, its global prevalence and trends, the risk factors for type 2 diabetes, and its complications and burden. It is a reference topic on disease epidemiology and does not provide diagnostic thresholds for individual care or treatment advice.

Core questions

• How common is diabetes worldwide, and how fast is prevalence rising?
• What distinguishes type 1, type 2, and gestational diabetes for epidemiologic purposes?
• Which modifiable factors drive type 2 diabetes, and what is its burden of complications?

Key concepts

• Chronic hyperglycaemia
• Type 1, type 2, and gestational diabetes
• Insulin resistance and beta-cell dysfunction
• Prediabetes / impaired glucose regulation
• HbA1c and diagnostic criteria
• Microvascular and macrovascular complications
• Adiposity as a driver of type 2 diabetes

Mechanisms

Type 2 diabetes, which accounts for the great majority of cases, arises from a combination of insulin resistance - reduced tissue response to insulin, strongly linked to excess and ectopic adiposity - and progressive pancreatic beta-cell dysfunction, leading to chronic hyperglycaemia. Sustained hyperglycaemia and associated metabolic disturbance drive both microvascular complications (retinopathy, nephropathy, neuropathy) and macrovascular disease, which is why diabetes is a major contributor to cardiovascular and renal burden (ADA Professional Practice Committee, 2024; Sun et al., 2022).

Clinical relevance

Diabetes epidemiology shapes screening policy, prevention programmes, and the planning of services for complications such as kidney and cardiovascular disease. This entry summarises how that population-level evidence is generated; it is not a guide to individual diagnosis or management, and the diagnostic cut-points referenced here are for classification and surveillance rather than personal medical decisions.

Epidemiology

Global diabetes prevalence among adults has risen to an estimated 10-11 percent, corresponding to over half a billion people living with diabetes, with projections of continued increase to the 2040s; a large share of cases remains undiagnosed, particularly in low- and middle-income countries (Sun et al., 2022). Diabetes is a leading contributor to disability-adjusted life years and to downstream cardiovascular and kidney disease (Vos et al., 2020), and it imposes substantial economic costs (Parker et al., 2024).

Evidence & guidelines

Global prevalence estimates come chiefly from the International Diabetes Federation's Diabetes Atlas and from the Global Burden of Disease programme (Sun et al., 2022; Vos et al., 2020). Diagnostic and classification criteria used for surveillance are set out in standards such as those of the American Diabetes Association (ADA Professional Practice Committee, 2024).

History

Although diabetes has been recognised clinically for millennia, its epidemiologic study as a population-scale chronic disease intensified in the second half of the twentieth century as type 2 diabetes prevalence rose alongside increasing adiposity and population ageing. Standardised diagnostic criteria - first based on glucose, later incorporating HbA1c - made consistent surveillance possible, and global atlases now track the epidemic across countries.

Debates

Where to set diagnostic thresholds for surveillance

Defining diabetes and prediabetes by glucose versus HbA1c, and the exact cut-points chosen, change measured prevalence and the size of the at-risk population; the choice involves trade-offs between sensitivity, comparability across settings, and clinical meaning.

Seminal works

• sun-2022
• vos-2020

Frequently asked questions

Why is diabetes prevalence rising so quickly?

The increase is driven mainly by type 2 diabetes, which tracks rising overweight and obesity, physical inactivity, dietary change, urbanisation, and population ageing across most of the world.

Are the diagnostic numbers here meant for self-diagnosis?

No. Classification and diagnostic criteria are referenced to explain how diabetes is counted in populations; individual diagnosis requires clinical assessment by a qualified professional.